FOLFIRINOX vs. gemcitabine/nab-paclitaxel for metastatic pancreatic cancer: A real-world study
Highlights • No significant OS or PFS differences were observed between regimens after matching.• Survival differences before matching may partly reflect patient selection.• ARID1A and RNF43 mutations were associated with shorter PFS with Gem/Nab-P.• Exploratory genomic associations require validation in larger prospec...